Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation

A legfontosabb adatok

Ki végzi
Wuhan Neurophth Biotechnology Limited Company
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Fázis
3. fázis
Résztvevők
95 fő vett részt
Kezdés
2024. szept. 19.
Várható befejezés
2030. máj. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • rAAV2-ND4
  • Sham (No Treatment)
A regiszteradat frissítve
2026. február 12.

Ki vehet részt

Életkor
12 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Age at the time of signing the informed consent form: the age of the subjects must be ≥ 12 years old and ≤ 75 years old
  • The clinical manifestation of all subjects is reduced visual acuity caused by LHON associated with ND4 mutation, while the reduced visual acuity lasted for > 6 months and < 10 years
  • The clinical manifestation caused by LHON is vision loss, with a visual acuity of ≥ 0.5 LogMAR and ≤1.68 in BCVA in both eye The genotype test result is that there is G11778A mutation in ND4 gene, and there are no other primary LHON-associated mutations in the mitochondrial DNA (mtDNA) (ND1[G3460A] or ND6[T14484C]) (confirmed by a CLIA-certified international laboratory) Pupils can be adequately dilated for a comprehensive eye examination and visual acuity test

Ki nem vehet részt

  • IVT drug delivery to any eye within 30 days prior to the screening visit History of vitrectomy in either eye
  • Participated in another clinical study and receive IP within 90 days prior to the screening visit; Exceptions: Subjects who have completed the clinical study of idebenone as IP within 90 days prior to the screening visit, and has completely discontinued idebenone at least 7 days prior to dosing are still eligible to participate in the study
  • Any eye has previously received ocular gene therapy
  • Have undergone ocular surgery of clinical relevance (per investigator's assessment) within 90 days prior to the screening visit
  • Any known allergy and/or hypersensitivity to the study drug or its constituents Contraindication to IVT injection in any eye
  • Presence of disorders or diseases of the eye or adnexa, excluding LHON, which may interfere with visual or ocular assessments, including optical coherence tomography during the study
  • Presence of systemic or ocular/vision diseases, disorders or pathologies, other than LHON, known to cause or be associated with vision loss, or whose associated treatment(s) or therapy(ies) is/are known to cause or be associated with vision loss
  • Presence of illness or disease that, in the opinion of the investigator, include symptoms and/or the associated treatments that can alter visual function, for instance cancers or pathology of the CNS, including multiple sclerosis (diagnosis of multiple sclerosis must be based on the 2010 Revisions to the McDonald Criteria) (Polman et al., 2011), and/or diseases or conditions that affect the safety of subjects participating in the study
  • History of recurrent uveitis (idiopathic or immune-related) or active ocular inflammation
  • History of drug or alcohol abuse (including heavy smoking, i.e. > 20 cigarettes per day or > 20 pack-years [equivalent to one pack a day for 20 years or 2 packs a day for 10 years])
  • Subjects with positive human immunodeficiency virus (HIV), syphilis and HCV antibodies are excluded; subjects who have clinically significant active infection requiring treatment as shown by hepatitis B test (defined as positive hepatitis B core antibody [HBcAb] or hepatitis B surface antigen [HBsAg], hepatitis B virus deoxyribonucleic acid (HBV-DNA) >1,000 copies /mL or >lower limit of quantitative detection with the local laboratory method) will be excluded
  • Narrow anterior chamber angle in any eye contra-indicating pupillary dilation
  • Presence of known/documented mutations, other than the LHON-related mutation, which are known to cause pathology of the optic nerve, retina or afferent visual system
  • Presence of optic neuropathy from any cause other than LHON
  • Subjects who refused to stop using idebenone
  • Female subjects who are breastfeeding or plan to breastfeed within the first 6 months after the administration of NR082 Injection
  • Unable to tolerate or unable or unwilling to comply with all the protocol requirements
  • Any other exclusions determined by the investigator

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The objective of this clinical study is to evaluate the safety and efficacy of NR082 in the treatment of LHON caused by mitochondrial ND4 gene mutation. This study will enroll subjects aged ≥ 12 years old and ≤ 75 years old to receive a single bilateral intravitreal (IVT) injection of NR082 to evaluate safety and efficacy. The clinical manifestations of all subjects are to be reduced visual acuity caused by LHON associated with ND4 mutation, with laboratory test showing G11778A mutation and reduced visual acuity lasted for >6 months and <10 years.

A vizsgálat 2 csoportja

  • Experimental: NR082 injectionA vizsgált kezelés

    4.5E9 viral genomes (vg) , 0.05 mL eye/dose , bilaterally

    Kezelés: rAAV2-ND4

  • Sham Comparator: sham-injectionSzínlelt kezelés, összehasonlításként

    Sham intravitreal injection (bilateral)will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.

    Kezelés: Sham (No Treatment)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Gene Therapy for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation
A regiszteradat frissítve
2026. február 12.